Table 3 Descriptive statistics of efficacy assessments; intention-to-treat (ITT) population

From: Safety and tolerability of IRL790 in Parkinson’s disease with levodopa-induced dyskinesia—a phase 1b trial

 

IRL790

Placebo

 

Median

Mean (SD)

Median

Mean (SD)

 

Baseline

Week 4

Baseline

Week 4

Baseline

Week 4

Baseline

Week 4

UDysRS

33

23*

33 (12)

22.6 (9)*

35

36.5

39.5 (19)

37.25 (14)

UPDRS 4 q 32–35

4

2

4.4 (2)

2.1 (1)

4.5

3.5

4.5 (1)

3.5 (2)

PKG, dyskinesia

6.8

3.9

5.6 (3)

3.9 (3)

6.7

4.7

11.8 (12)

6.3 (6)

PKG, bradykinesia

25.5

24.6

24.5 (5)

26.2 (6)

17.6

20.1

17.9 (4)

19.9 (2)

UPDRS part 1

3

2

2.8 (2)

2.8 (2)

3

2

3.2 (1)

3.0 (2)

UPDRS part 2

13

10

12 (5)

10.4 (5)

13

12

14.2 (8)

13.8 (8)

UPDRS part 3

14

14

18.2 (10)

15.7 (5)

19

16

19.8 (7)

15 (2)

UPDRS part 4

9

6

7.8 (2)

6.3 (2)

8.5

8

8.7 (2)

7.5 (3)

  1. *P < 0.01; Wilcoxon signed rank sum test
Back to article page